chufangao/CTO huggingface dataset:
Clinical trial NCT00904345: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
Official title: Phase II Study of RT Concurrent w/ Cetuximab in Patients w/ Locally Advanced Head & Neck SCC Who Do Not Qualify For Standard Chemotherapy Due To Age >70 Or Co-Morbidities
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Stopped early for funding and efficacy reasons.
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2009-04-30
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Official title: A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Sponsor: Sumitomo Pharma America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision to terminate further development of the program.
Enrollment: 74.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-26
Primary completion date: 2024-01-10
Completion date: 2024-01-10
Plan to share individual participant data: NO
Clinical trial NCT04383210: Study of Seribantumab in Adult Patients with NRG1 Gene Fusion Positive Advanced Solid Tumors
Official title: CRESTONE: a Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Sponsor: Elevation Oncology (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 54.0 (ACTUAL)
Number of arms: 3.0
Start date: 2024-02-28
Primary completion date: 2024-02-28
Completion date: 2024-02-28
Plan to share individual participant data: NO
Clinical trial NCT03128905: Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis
Official title: Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition (CPPD) Arthritis: Open-label, Randomized, Multicenter, Equivalence Trial of Efficacy and Safety
Acronym: COLCHICORT
Sponsor: Lille Catholic University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 111.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-05
Primary completion date: 2022-05-13
Completion date: 2022-05-13
Plan to share individual participant data: NO
Clinical trial NCT03691376: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Official title: A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of funding
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-08
Primary completion date: 2021-01-30
Completion date: 2024-06-24
Clinical trial NCT04739566: Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer
Official title: Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)
Acronym: ANAPLAST-NEO
Sponsor: Saint Petersburg State University, Russia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-22
Primary completion date: 2023-12-22
Completion date: 2023-12-22
Plan to share individual participant data: NO
Clinical trial NCT05628545: Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Official title: Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Sponsor: Guangdong GD Kongming Biotech LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: COVID1-19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-11-01
Primary completion date: 2023-02-28
Completion date: 2024-10-31
Plan to share individual participant data: NO
Clinical trial NCT04455139: A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
Official title: A Phase II Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma, With Randomization Depending on the Site of Relapse or on Previous Treatment
Acronym: EuRbG2018
Sponsor: University of Lausanne Hospitals (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulties in recruiting patients due to changing in treatment standards for the target population
Enrollment: 2.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-11-15
Primary completion date: 2023-05-22
Completion date: 2023-05-22
Clinical trial NCT03921294: HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor
Official title: Prospective, Single-arm, Open-label Use of Hemlibra (Emicizumab) to Treat Hemophilic Pseudotumor
Sponsor: Indiana Hemophilia &Thrombosis Center, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Global COVID-19 pandemic prevented further study visits or enrollment.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-15
Primary completion date: 2022-03-16
Completion date: 2022-03-16
Baseline population: Patients with Factor VIII deficiency and hemophilia pseudotumor.
Plan to share individual participant data: YES
IPD sharing description: We will share resources and data from this project through collaborative publications in the scientific literature as well as through national, regional and international conference presentations. We will also share our methods and findings in a prompt manner with regional, national and international stakeholders to ensure that findings will be readily available to other researchers and clinicians with clinical or scientific interest in the subject area. Individual participant data that underlie the results reports in publications, reports or presentations (including text, tables, figures and appendices) will be shared after de-identification.
IPD time frame: IPD and additional information on study methods will be made available starting 9 months after publication or conclusion of the study and ending 36 months following publication or study conclusion.
IPD access criteria: IPD and study information will be shared with investigators whose proposed use of the data has been approved by an independent review committee (learned intermediary), whose proposals are methodologically sound, and for purposes that are consistent with the aims of the underlying research. Proposals will be reviewed by the Principle Investigator, Dr. Amy Shapiro, and may be submitted to ashapiro@ihtc.org. Requestors will be required to sign a data access and use agreement.
Clinical trial NCT04510285: A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Official title: A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-10
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Plan to share individual participant data: YES
IPD sharing description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Clinical trial NCT04929626: Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus
Official title: Comparison of Doses of Nebulized Magnesium Sulphate as an Adjuvant Treatment With Salbutamol in Children With Status Asthmaticus
Sponsor: Ziauddin University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 126.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-01
Primary completion date: 2022-11-12
Completion date: 2022-11-12
Plan to share individual participant data: NO
Clinical trial NCT03719898: Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Official title: A Phase II Study of Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Sponsor: Fox Chase Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Slow accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-06
Primary completion date: 2020-03-18
Completion date: 2020-06-16
Clinical trial NCT03363503: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD
Official title: Comparison of Efficacy and Safety of Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Treatment Administered Via Capsair and Original Product Seretide Diskus 500 mcg Inhalation Powder Treatment in Patients With Moderate-severe Chronic Obstructive Pulmonary Disease (COPD)
Acronym: COPD
Sponsor: Neutec Ar-Ge San ve Tic A.Ş (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Adequate number of patients could not be reached in the relevant centers.
Enrollment: 64.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-13
Primary completion date: 2022-04-13
Completion date: 2022-04-13
Clinical trial NCT05146882: An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
Official title: A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients With PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Update to Program Design - No Participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-31
Primary completion date: 2022-05-23
Completion date: 2022-05-23
Clinical trial NCT04372017: Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
Official title: Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection
Sponsor: Sanford Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Unlikelihood of benefit based on other studies.
Enrollment: 1.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-05-14
Primary completion date: 2021-06-04
Completion date: 2021-06-04
Baseline population: No subjects or data analyzed. Study was closed to enrollment before analysis.
Plan to share individual participant data: NO
Clinical trial NCT03233724: Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Official title: Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to drug supply issues.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-11
Primary completion date: 2021-10-06
Completion date: 2021-10-26
Baseline population: No participants were enrolled on Decitabine 0.17mg/kg + Tetrahydrouridine 10mg/kg Every (q) Tuesday,Wednesday (TW) x 2 Weeks q3Weeks.
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the Database of Genotypes and Phenotypes (dbGaP).
IPD time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.
IPD access criteria: Clinical data will be made available via subscription to the Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Clinical trial NCT01887522: Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
Official title: Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma
Acronym: VINILO
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: the results of the interim analysis are clear with a significant advantage in terms of PFS in favor of the control arm (Vinblastine alone) over the investigational arm (Vinblastine + Nilotinib).
Enrollment: 144.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-06
Primary completion date: 2019-04-20
Completion date: 2021-04-25
Clinical trial NCT05376319: PR3-AAV Resilient Remission or PRRR
Official title: A Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effect of Obinutuzumab Versus Rituximab in PR3-Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding was withdrawn by sponsor.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-06-30
Primary completion date: 2024-05-07
Completion date: 2024-05-07
Limitations and caveats: Study was discontinued early due to funding termination by industry sponsor.
Plan to share individual participant data: NO
Clinical trial NCT02099864: Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Official title: Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Sponsor: OHSU Knight Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-02-05
Primary completion date: 2019-10-01
Completion date: 2024-07-08
Clinical trial NCT03043547: Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Official title: A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Acronym: NALIRICC
Sponsor: AIO-Studien-gGmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-24
Primary completion date: 2021-12-08
Completion date: 2022-03-08
Plan to share individual participant data: NO
Clinical trial NCT06056596: Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
Official title: Intra-ocular Penetration of Oral Lamivudine and Measurement of Systemic Inflammatory Markers in Patients Undergoing Rhegmatogenous Retinal Detachment Surgery
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Treatment approach changed, and insufficient population
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-30
Primary completion date: 2024-09-06
Completion date: 2024-09-06
Plan to share individual participant data: YES
Clinical trial NCT01967238: An Open Label Study of IgG Fc Glycan Composition in Human Immunity
Official title: An Open Label Study of IgG Fc Glycan Composition in Human Immunity
Sponsor: Rockefeller University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Inadequate enrollment
Enrollment: 129.0 (ACTUAL)
Number of arms: 3.0
Start date: 2013-03-31
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT05183360: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated
Official title: Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Dose and Multiple Rising Oral Doses of BI 706321 in Healthy Japanese Male Subjects and Single Oral Dose of BI 706321 in Healthy Chinese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company decision
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-02-03
Primary completion date: 2022-08-22
Completion date: 2024-08-08
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:~1. studies in products where Boehringer Ingelheim is not the license holder;~2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;~3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datasharing
Clinical trial NCT02618577: Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
Official title: Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET
Acronym: NOAH
Sponsor: Atrial Fibrillation Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.
Enrollment: 2608.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Clinical trial NCT04605094: Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
Official title: A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study did not meet the primary endpoint.
Enrollment: 194.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-12
Primary completion date: 2022-04-25
Completion date: 2022-09-13
Baseline population: The Full Analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study drug, irrespective of their protocol adherence and continued participation in the study.
Limitations and caveats: The study was terminated as the study did not support the continued development of benralizumab for the indication of AD.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT02582775: MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
Official title: MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions
Sponsor: Masonic Cancer Center, University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 8.0
Start date: 2016-03-31
Primary completion date: 2022-11-15
Completion date: 2023-07-26
Clinical trial NCT04349917: Large-scale Brain Organization During Cognitive Control in ADHD
Official title: Large-scale Brain Organization During Cognitive Control in ADHD
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-16
Primary completion date: 2020-03-14
Completion date: 2020-03-14
Clinical trial NCT03199547: Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death
Official title: Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis and Death: a Phase III Double-blind Randomized Clinical Trial
Acronym: PregnAnZI-2
Sponsor: London School of Hygiene and Tropical Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 11985.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-21
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Plan to share individual participant data: NO
Clinical trial NCT05375604: A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
Official title: Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC)
Sponsor: Codiak BioSciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company Bankruptcy
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-28
Primary completion date: 2023-05-25
Completion date: 2023-05-30
Plan to share individual participant data: NO